Document is current
Any future updates will be listed below
-
Authors
Shi, Yunhua
Reker, Daniel https://orcid.org/0000-0003-4789-7380
Byrne, James D.
Kirtane, Ameya R. https://orcid.org/0000-0002-3779-0363
Hess, Kaitlyn
Wang, Zhuyi
Navamajiti, Natsuda https://orcid.org/0000-0002-0346-1756
Young, Cameron C. https://orcid.org/0000-0001-7323-4834
Fralish, Zachary
Zhang, Zilu
Lopes, Aaron
Soares, Vance
Wainer, Jacob https://orcid.org/0000-0002-4845-228X
von Erlach, Thomas
Miao, Lei
Langer, Robert https://orcid.org/0000-0003-4255-0492
Traverso, Giovanni https://orcid.org/0000-0001-7851-4077
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (EB000244)
U.S. Department of Health & Human Services | National Institutes of Health (EB000244)
- License Information
-
More Information
Article History
Received: 9 November 2020
Accepted: 1 October 2023
First Online: 20 February 2024
Change Date: 16 December 2025
Change Type: Update
Change Details: In the version of the Supplementary information initially published, the “MCT1” image in Supplementary Fig. 5b was a duplicate of the “SNAT2” image in the same panel. Additionally, the figure legend to Supplementary Fig. 15 has been corrected to “Original gel images for Supplementary Fig. 5”. The corrected Supplementary information is now available online.
Competing interests
: Y.S., D.R., V.S., R.L. and G.T. are co-inventors on a provisional patent application encompassing the work described. T.v.E., R.L. and G.T. have a financial interest in Vivtex, a biotechnology company applying ex vivo models for high-throughput drug formulation development. D.R. acts as a consultant to the pharmaceutical and biotechnology industry. Complete details of all relationships for profit and not for profit for G.T. and for R.L. can be found in the Supplementary Information.
